{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T20:04:12Z","timestamp":1762459452653},"reference-count":7,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2017,1,20]],"date-time":"2017-01-20T00:00:00Z","timestamp":1484870400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2017,1,20]],"date-time":"2017-01-20T00:00:00Z","timestamp":1484870400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Gene Ther"],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.1038\/cgt.2016.67","type":"journal-article","created":{"date-parts":[[2017,1,20]],"date-time":"2017-01-20T12:28:38Z","timestamp":1484915318000},"page":"45-47","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["OBP-401-GFP telomerase-dependent adenovirus illuminates and kills high-metastatic more effectively than low-metastatic triple-negative breast cancer in vitro"],"prefix":"10.1038","volume":"24","author":[{"given":"S","family":"Yano","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K","family":"Takehara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H","family":"Kishimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H","family":"Tazawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y","family":"Urata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S","family":"Kagawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Bouvet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T","family":"Fujiwara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R M","family":"Hoffman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,1,20]]},"reference":[{"key":"BFcgt201667_CR1","volume-title":"Devita, Hellman and Rosenberg\u2019s Cancer: Principles and Practice on Oncology (Cancer Principle and Practice of Oncology)","author":"VT Devita Jr","year":"2015","unstructured":"Devita VT Jr, Lawrence TS, Rosenberg SA (eds). 2015 Devita, Hellman and Rosenberg\u2019s Cancer: Principles and Practice on Oncology (Cancer Principle and Practice of Oncology) 10th ednWolters Kluwer Health: (USA) ."},{"key":"BFcgt201667_CR2","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1056\/NEJMra1001389","volume":"363","author":"WD Foulkes","year":"2010","unstructured":"Foulkes WD, Smith IE, Reis-Filho JS . Triple-negative breast cancer. N Engl J Med 2010; 363: 1938\u20131948.","journal-title":"N Engl J Med"},{"key":"BFcgt201667_CR3","doi-asserted-by":"publisher","first-page":"3817","DOI":"10.21873\/anticanres.11222","volume":"36","author":"S Yano","year":"2016","unstructured":"Yano S, Takehara K, Miwa S, Kishimoto H, Tazawa H, Urata Y et al. In vivo isolation of a highly-aggressive variant of triple-negative human breast cancer variant MDA-MB-231 using serial orthotopic transplantation. Anticancer Res 2016; 36: 3817\u20133820.","journal-title":"Anticancer Res"},{"key":"BFcgt201667_CR4","unstructured":"Yano S, Takehara K, Tazawa H, Kishimoto H, Kagawa S, Fujiwara T et al. Comparison of in vitro invasiveness of high- and low-metastatic triple negative human breast cancer visualized by color-coded imaging. In Vitro Cell Dev Biol-Animal. (e-pub ahead of print)."},{"key":"BFcgt201667_CR5","unstructured":"Yano S, Takehara K, Tazawa H, Kishimoto H, Kagawa S, Fujiwara T et al, High-metastatic triple-negative breast cancer variants selected in vivo become chemoresistant in vitro. In Vitro Cell Dev Biol Anim (in press)."},{"key":"BFcgt201667_CR6","doi-asserted-by":"publisher","first-page":"6495","DOI":"10.1158\/1078-0432.CCR-13-0742","volume":"19","author":"S Yano","year":"2013","unstructured":"Yano S, Tazawa H, Hashimoto Y, Shirakawa Y, Kuroda S, Nishizaki M et al. A genetically engineered oncolytic adenovirus decoys and lethally traps quiescent cancer stem-like cells into S\/G2\/M phases. Clin. Cancer Res 2013; 19: 6495\u20136505.","journal-title":"Clin. Cancer Res"},{"key":"BFcgt201667_CR7","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1002\/jcb.24305","volume":"114","author":"A Uchugonova","year":"2013","unstructured":"Uchugonova A, Zhao M, Weinigel M, Zhang Y, Bouvet M, Hoffman RM et al. Multiphoton tomography visualizes collagen fibers in the tumor microenvironment that maintain cancer-cell anchorage and shape. J Cell Biochem 2013; 114: 99\u2013102.","journal-title":"J Cell Biochem"}],"container-title":["Cancer Gene Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/cgt201667.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/cgt201667","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/cgt201667.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,22]],"date-time":"2022-03-22T12:14:17Z","timestamp":1647951257000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/cgt201667"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1,20]]},"references-count":7,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,2]]}},"alternative-id":["BFcgt201667"],"URL":"https:\/\/doi.org\/10.1038\/cgt.2016.67","relation":{},"ISSN":["0929-1903","1476-5500"],"issn-type":[{"value":"0929-1903","type":"print"},{"value":"1476-5500","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,1,20]]},"assertion":[{"value":"30 September 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2016","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 October 2016","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2017","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"YU is the President & CEO of Oncolys BioPharma, Inc., the manufacturer of OBP-401 (Telomescan). HT and TF are consultants of Oncolys BioPharma, Inc. The remaining authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}